Kaur S, Kerkar R A, Maheshwari A, Shylasree T S, Gupta S, Deodhar K
Depatment of Gynecological Oncology, Tata Memorial Hospital, Mumbai, India.
Depatment of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
Indian J Cancer. 2016 Apr-Jun;53(2):288-291. doi: 10.4103/0019-509X.197719.
To analyze clinical characteristics, patterns of relapse, and treatment outcomes of clearcell carcinoma of the ovary (CCO).
Case files of 51 patients diagnosed with CCO between 2003 and 2010 were reviewed.
The median age at diagnosis was 48 years (27-64 years). Fifty percent presented with nonspecific gastrointestinal symptoms. The median serum Ca125 was 74 IU/ml (6-1567 U/ml). Optimal cytoreduction was achieved in 32 (62.7%) patients. Of the 51 patients in this series, 34 (66.6%) had Stage I disease; Stage Ia in 12 (23.6%), Stage Ib in 1(1.9%), and Stage Ic in 21 (41.1%). Thirteen (25.6%) presented with Stage III and 4 (7.8%) with Stage IV. No patient had Stage II disease. All patients received 4-6 cycles of platinum-based combination chemotherapy. There were 18 relapses (35.2%), with disease-free intervals <6 months in 9, 6-12 months in 4, and >12 months in 5, respectively. Of them 33.3% had a recurrent pelvic mass. The median survival after relapse was 14 months. There were 13 deaths, 11 due to disease progression, 1 due to chemo toxicity, and 1 unrelated to disease. At a median follow up of 28 months, disease-free survival (DFS) and overall survival (OS) of patients with Stage I-Stage II (early) disease was 64% and 80%, respectively. In patients with advanced disease, that is, Stages III and IV, DFS and OS were 35% and 38%, respectively.
CCO generally presents at an early stage but has a high propensity for relapse. Patients with early-stage disease have a relatively good prognosis as compared with those with advanced-stage disease.
分析卵巢透明细胞癌（CCO）的临床特征、复发模式及治疗结果。
回顾了2003年至2010年间51例诊断为CCO的患者病历。
诊断时的中位年龄为48岁（27 - 64岁）。50%的患者出现非特异性胃肠道症状。血清Ca125的中位值为74 IU/ml（6 - 1567 U/ml）。32例（62.7%）患者实现了最佳细胞减灭术。在本系列的51例患者中，34例（66.6%）为Ⅰ期疾病；12例（23.6%）为Ⅰa期，1例（1.9%）为Ⅰb期，21例（41.1%）为Ⅰc期。13例（25.6%）为Ⅲ期，4例（7.8%）为Ⅳ期。无患者为Ⅱ期疾病。所有患者均接受了4 - 6周期的铂类联合化疗。有18例复发（35.2%），无病间期分别为<6个月的9例、6 - 12个月的4例和>12个月的5例。其中33.3%有盆腔复发肿块。复发后的中位生存期为14个月。有13例死亡，11例死于疾病进展，1例死于化疗毒性，1例与疾病无关。中位随访28个月时，Ⅰ - Ⅱ期（早期）疾病患者的无病生存期（DFS）和总生存期（OS）分别为64%和80%。在晚期疾病（即Ⅲ期和Ⅳ期）患者中，DFS和OS分别为35%和38%。
CCO通常在早期出现，但复发倾向较高。与晚期疾病患者相比，早期疾病患者的预后相对较好。
